SCHEMBL17791102

SCHEMBL17791102

Cc1cc(F)c(C(=O)Cl)c(C(F)(F)F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
KIF11 P52732 1/20 0.35
ALDH1A1 P00352 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NOTUM Q6P988 2/20 0.32
AKR1C3 P42330 2/20 0.31
AKR1C2 P52895 2/20 0.31
MAPT P10636 2/20 0.31
RAB9A P51151 2/20 0.31
CA2 P00918 1/20 0.31
POLB P06746 1/20 0.31
TYR P14679 1/20 0.31
TP53 P04637 1/20 0.31
KCNQ3 O43525 2/20 0.31
KCNQ2 O43526 2/20 0.31
KCNE1 P15382 2/20 0.31
KCNQ1 P51787 2/20 0.31
PGK1 P00558 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9712503 0.82 HDAC1 (0.38) SMN1; SMN2HTTLMNAALDH1A1L3MBTL1
SCHEMBL15901970 0.80 CES2 (0.42) KIF11NOTUMMAPT
SCHEMBL8927424 0.74 CA1 (0.36) KIF11ALDH1A1L3MBTL1NOTUMCA2
SCHEMBL3023015 0.73 CES2 (0.42) SMN1; SMN2HTTLMNANOTUMMAPT
SCHEMBL29244555 0.71 TMPRSS4 (0.35) SMN1; SMN2HTTLMNAKIF11NOTUM
SCHEMBL16408244 0.71 CES2 (0.45) ALDH1A1MAPT
SCHEMBL18394005 0.71 CES2 (0.47) NOTUMMAPT
SCHEMBL476764 0.70 CES2 (0.48) ALDH1A1MEN1KMT2A
SCHEMBL3894397 0.70 RAPGEF4 (0.36) SMN1; SMN2KIF11ALDH1A1CA2POLB
SCHEMBL18272234 0.70 HTR2A (0.39) SMN1; SMN2KIF11ALDH1A1CA2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
US-20160152561-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2016-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A SMN1; SMN2 349/4885HTT 1309/4885LMNA 2874/4885
US-20160152561-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN1A, SCN5A SMN1; SMN2 282/4885HTT 1784/4885LMNA 3605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.